Navigation Links
NeurogesX to Present at Oppenheimer & Co Healthcare Conference
Date:10/28/2010

SAN MATEO, Calif., Oct. 28 /PRNewswire/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced today that Anthony DiTonno, President and Chief Executive Officer, is scheduled to present at the 21st Annual Oppenheimer & Co Healthcare Conference, to be held November 2-3, 2010 at the Waldorf-Astoria in New York, NY.

Mr. DiTonno and Stephen Ghiglieri, Executive Vice President, Chief Operating Officer and Chief Financial Officer, will be available to respond to questions immediately following the presentation and to participate in one-on-one meetings with investors attending the conference. Event: 21st Annual Oppenheimer & Co Healthcare ConferenceDate: Wednesday, November 3, 2010Time: 3:55pm EDT Place: Waldorf-Astoria, New York, NY (Basildon Room)The presentation will be webcast live and can be accessed by visiting the investor relations section of NeurogesX' website at www.neurogesx.com. The webcast will be archived for 90 days.

About NeurogesX, Inc.NeurogesX, Inc. (Nasdaq: NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza® (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.

The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.

The Company is currently preparing to submit a supplemental NDA for Qutenza for the management of pain due to  HIV- distal sensory neuropathy, or HIV-DSP, also known as HIV-associated neuropathy, or HIV-AN.   Additionally, the Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies.

The Company's early-stage product pipeline includes pre-clinical compounds which are prodrugs of acetaminophen and various opioids. The Company has evaluated these compounds in vitro and in vivo.

Safe Harbor StatementThis press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to: statements about the preparation and potential submission of a label expansion NDA for Qutenza. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in the submission of the supplemental NDA for Qutenza; data submitted may not be sufficient to support FDA approval of Qutenza in the treatment of pain associated with HIV-AN; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of an expanded label for Qutenza, including as a result of physician or patient reluctance to use Qutenza; Qutenza and NeurogesX' other product candidates may have unexpected adverse side effects; and potential alternative therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX, Inc.Stephen Ghiglieri

Executive Vice President, COO

and CFO

(650) 358-3310

The Ruth GroupSara Pellegrino (investors)

(646) 536-7002

spellegrino@theruthgroup.comJason Rando (media)

(646) 536-7025

jrando@theruthgroup.com
'/>"/>

SOURCE NeurogesX
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. NeurogesX Announces Positive Results from Second Phase 3 Clinical Trial in Postherpetic Neuralgia
2. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
3. NeurogesX Completes Enrollment in Confirmatory Phase 3 Clinical Trial for Painful HIV Distal Sensory Polyneuropathy
4. NeurogesX Announces Preliminary Results from Second Phase 3 Clinical Trial in HIV-DSP
5. NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology
6. NeurogesX Initiates Dosing in Phase 1 Clinical Trial for NGX-1998 Capsaicin Liquid Formulation
7. NeurogesX Announces Publication of Phase 3 Data for QUTENZA(TM) (NGX-4010) in Postherpetic Neuralgia (PHN) by The Lancet Neurology
8. NeurogesX Receives FDA Orphan Drug Designation for Qutenza(TM) for Treatment of Postherpetic Neuralgia
9. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
10. NeurogesX to Present at JMP Securities Healthcare Focus Conference
11. NeurogesX to Hold Conference Call to Discuss Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... TUCSON, Ariz. , May 3, 2016  As ... twice contracted rheumatic fever, which damaged his heart. ... But by June 2013, Shepherd,s heart was ... days from death. On June 20, 2013, the ... temporary Total Artificial Heart (TAH-t). Like a heart transplant, ...
(Date:5/3/2016)... 3, 2016  While you may be familiar with watching a film or TV show in ... ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized reseller of the ... Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... , May 3, 2016 ... pay $55 million to a woman who says its ... court awarded Gloria Ristesund $5 million in ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ... accusations against the company. In February, the same court ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... McLaughlin & Smoak Benefits as the latest addition to its family of Partner ... dedicated team of compliance, wellness, human resources, and health care consumerism specialists. , ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... and Make-A-Wish grants the most heartfelt wishes of these children. The wishes ... medical treatment. President and CEO of Make-A-Wish Mississippi, Brent Wilson said, “In ...
(Date:5/5/2016)... ... May 05, 2016 , ... Michael Lanteri Agency in Fort ... assist the people of their local community. The agency pledges to select a ... Their hope is to bring awareness to important local causes with fundraising and ...
(Date:5/5/2016)... ... May 05, 2016 , ... A recent survey by the Midwest Business ... employees to understand and use the free preventive care benefits available to them as ... groups of large, self-insured public and private employers, MBGH found that only 10% of ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... ongoing community enrichment program serving families of greater Dubuque, IA. The current campaign ... reserve and honorably discharged veterans. Donations to Veteran’s Freedom Center may now be ...
Breaking Medicine News(10 mins):